Sofosbuvir/velpatasvir/sofosbuvir (Epclusa) approved for use in paediatrics in the EU for treatment of chronic hepatitis C infection

The licence extension will cover use in patients from 6 years of age weighing at least 17kg regardless of HCV genotype or liver disease severity. Approval was based on data showing that treatment resulted in a 93% cure rate in genotype 1, and 100% cure rates in other genotypes.